Skip to main content
2522 results
Article

We respond to NICE decision to approve Enhertu for routine use on the NHS for people with HER2-positive metastatic breast cancer

Rachael Franklin, deputy chief executive at Breast Cancer Now, said: “We’re thrilled that today NICE has confirmed continued access to Enhertu for people with HER2-positive metastatic breast cancer on the NHS in England. This news comes just two weeks after the landmark announcement that the drug would be made available to people with HER2-low metastatic breast cancer.